On May 23, Mirxes Holding Company Limited (“Mirxes”, stock code: 02629.HK) officially listed on the Main Board of the Hong Kong Stock Exchange. The issuer priced its global offering at HK$23.3 per share, issuing approximately 46,620,000 shares and raising approximately HK$1.086 billion, making it the largest medical device 18A IPO since 2022.

Mirxes is a Singapore-headquartered miRNA technology company that is making diagnostic solutions for the screening of diseases accessible across key markets in Asia, including Singapore and China.

Davis Polk & Wardwell, Venture Law LLC, Jingtian & Gongcheng, Ogier, and Mewburn Ellis LLP acted as legal advisors to the issuer, covering Hong Kong and U.S. law, Singapore law, PRC law, Cayman Islands law, and intellectual property laws in the United Kingdom, Germany and Europe, respectively.

Wilson Sonsini Goodrich & Rosati and Baker & McKenzie advised the joint sponsors and underwriters on Hong Kong and U.S. law, while Commerce & Finance Law Offices advised on PRC law.